joining everybody, processing call Good but to us. Yvonne. you apologize the interested so start. for dialers Thank you, get now. Apologies delays, investors ready late and of center thank the afternoon the to, for started trouble for The had dialing in,
finance accounting earlier Jones have week. Life and for welcoming excellent month of team the place a NovaBay. Jason’s only this us his to company It’s background by would experience. Sciences and an than industry Andy Chief to Andy in fit to as departure. and more XX after Andy in like one permanent this start to exciting him And Officer I make joined public NovaBay. accounting call has years Financial also
temporary basis on to special pleased role that and extend April. of in at to in a I’m like a has smooth us semi a retirement the Christopher, to a thanks stay stepped agreed out seamlessly with came Lynn transition. consulting of beginning on would support to say I who to Lynn
At mandate shelter of Bay having capabilities. we all the Area, our San place worked the in requirements with in headquarters of with from our employees are the Francisco home complying
Our following full team, field the organization, a entire including sales prepared restrictions. is support the these of full to to operations lifting a return –
everywhere KNXX less We are pandemic gratified people at our commitment X the than units well-being avenova.com are sold. the by in-demand to reasonable milestone honor masks months during through health two ago, COVID-XX million selling of began to We and offering nearing products and the of prices. already
are not that high-risk these in point a – are situations. that for are are designated designed reserved for masks general sanitarian as the designated and of As disposable masks as medical These masks that clarification, KNXX are the professionals NXX public.
across that to struggled they’re people remind I’d country masks to immediately. find masks, many the While and stock we to have ready out in ship like everybody
of that ordering. offering biggest them day two can have a to the of One within mask is or benefits our customers
EAU Authorization, for known we an we for point-of-care approval a XX announced update we rapid that to had to COVID-XX as indeed have the less an agreement many I’d assigned reviewer also the did EUA. April – Emergency on everybody finger than we like us. and that, have also Use FDA Also, U.S. asked know also FDA on with month Since distribution for file test. FDA ago, the a me antibody prick people then, a
guidance provide investors, their changing FDA for government Because with few I in receive most guidance review. just of are date, authorized and other are antibody currently within FDA cannot individual reports XXX when To institutions that been we past Over if occurring XX the our queue only almost under to an approval. antibody FDA or tests the will tests days. have the those EUA, the daily,
data to kits they the that sale. unsure can We’re clearing back more however, supposed will aggressive way, our to that than hurdles everything just FDA the approval hear and we’re prior for additional from may Even FDA though no get test follow-up. very doing about been our regulatory require to may with later whether we’re throw know XX, we have
more increase this as revenue year, first our for higher than Avenova and And prior sales driven very importantly, year for half a product Avenova QX online non-prescription June. million. We during reviewing all product was net first sales. results, the XX% last This of accounted was sales unit the Avenova consumer was for mostly of quarter financial time. $X.X over by In a the introduced
We view the continue the greatest to opportunity for going Avenova channels holding forward.
impacted success Avenova strategy to offerings effort in industry-wide an sales having years. also with We’re diversify has offset that our past our – in product in to channels prescription reimbursement have and that changes
has historically, pronounced been results, with plan first in annual impact recall may the most You that the on health reset quarter deductibles.
nonprescription for economics was consumers We commercial shift on by shifting online NovaBay. the to our to Avenova for took strategy XXXX by sales This focus prescription followed promoting of with directly Avenova included eyecare sales. significant that a professionals. opportunities Avenova been launch sales in in actions with to our have U.S. of reduction QX This force the best
sales and That lowered said, sales. pricings prescription gross-to-net already online
the for While came XX% total units from direct-to-consumer of all of revenue. Avenova only channel, XX% accounted the it sold quarter during
shift. of in were these of XX% our organization decline accompanied size sales expenses the following a sales However, a of our reduction year-over-year the strategic by operating as part
was year-over-year in narrowed XX% So it loss operating significant by improvement as
KNXX on like efforts masks. everyone sell to update to our also I’d
X mentioned with in nearing of that earlier, having sales I occurred April. million pricing. discount sold the most for orders units, As our includes large This several a sale we
Margins all confidently keeping transport shy costs – providing we’re April the of revenue did less to can these done because QX. we are from pricing, commitment price that much at of Although from away offer but I’m of in high guidance, on QX to the possible have we that our with are that’s the with most more but expediting masks going masks the I shipping month during and reflecting than China. than because say reasonable our above in Nova, we
Currently, the masks orders orders well. to future growth most the in large attributable as large of we in will and from volume expect sales is May, come
sales through least dust, pollution, micro through for and remain While steady. making including KNXX to fairly at pollen filtering particles, out ideal are we effective of organisms, air public a website, at airborne expect places. them masks XX% in wearing These
response. the approval use KNXX our to for and emergency submitted FDA have masks We awaiting are a
to these masks, not will it required the masks. the comfort obtaining quality in our our customers hopefully give is While sell EUA added approval of
combo In to for to the mask kit purchase. an along $XXX, offering bottles with of we’re masks XX two Avenova. the and masks antimicrobial properties perfect Avenova Avenova, promote a of effort is complement with a
bulk are companies are placing pack of their goodwill. that In a finding combo fact, some for we as orders employees of this gesture
submitted As point-of-care presence a I use U.S. mentioned emergency COVID-XX the the we for antibody in person’s approval. antibodies blood. possible this that exclusive of has fluorecare test rapid determines rights NovaBay COVID-XX rapid distribute the earlier, test to
results our by This antibodies, sales XX is detection not test. and healthcare for the professionals The by to test uses in a marketed an minutes. is be available administered drop of This be the healthcare with at-home of test team COVID-XX a approximately professionals. point-of-care only to blood will
response replaces the in antibody test by by presence to generated The which the COVID-XX COVID-XX is to both antibody coronavirus, the IgM the antibody antibodies, [ph] body generated the first are response of and body the infection. specifically in then predominant IgG, IgM IgG as response the infection. detect and is to antibody the in generated a IgM usually the
citing COVID-XX experts country effective been health for masks could tracing a is infected those the who with across detecting an COVID-XX. testing single prick in Public need for IgG, and procedures critical testing step provide and leaders minutes important in infection. results cost with This way available antibodies, are and of tracking IgM our finger a have
to the – test to minutes include at blood test However, slightly shorter of the kits that microliters testing will begin XX, minutes, accuracy fluorecare to or XX secure specimen which factors for a as require. fact comparable time opposed itself tests sales market. improve other as Should test tests contained similar these larger is also additional The force reagents opposed equipment, we healthcare need ancillary U.S. using the our materials, specimen without our blood How differentiating to very XX on offering and FDA, XX approval the to the from professionals.
of because receive ever-changing we marketing give the timeline that the cannot for Please we will review or guidance at all. whether commercial landscape, for regulatory clearance note on
kits. this data giving The they or FDA as the FDA soon, but us as on week hear to a put sell well clearance Monday this the to a require of from by supposed will out chance and before almost just testing more the We’re back guidance that today make certainty. there’s
on sales update engaged restrictions. pandemic and virtually stopped. following sales is an support e-mail Avenova sales slowdown working we contact lifting business, in-office on channels, saw place As the in the eyecare to force as phone our specialists home, direct prescription visits our with Avenova shelter and All in in a and through patient from impact of our the keeping specialists
total, becoming of we may a online emphasizes for of life Consumer a messaging new base cost-effectively we quality with the expand introduction Branding that and are pursuing recall percentage With reinvigorating a of to You sales. our Avenova growing online packaging through previously sales customer the announced Refresh that strategy themes.
relationships, our strategy. by opportunity growth the through affiliate to refreshed with branding to which increase are open we’re to are aligned sales pleased the our reception We and
reiterate of our in supply to supplies confidence third-party and we our been are available two manufacturers. manufacturing suppliers And All sufficient at more the our lastly, utilized to needs. product. materials in sufficient other has quantities believe and raw from I uninterrupted meet be to expected Avenova want manufacturing contract Avenova than having of
Now, over our more detail. I’ll financial to turn in the review performance to Andy call
